HP and myeloid sarcoma: In conclusion, MS patients appear to differentially recognize certain Hp antigens compared to healthy individuals; this recognition differs amongst SPMS and RRMS further underlining the complexity of the potential implication of anti-Hp antibody responses in the immune dysregulation of MS.